Founder & CEO
Dr. Andrew Chadeayne is the Founder and CEO of CaaMTech. Prior to founding CaaMTech, Andrew served as Chief Innovations Officer at ebbu, Inc. where he managed all aspects of the company’s patent strategy leading up to its sale to Canopy Growth Corporation in 2018. Over the past 20 years, Andrew has worked in virtually every area of chemical innovation, including Director of Intellectual Property for NewMarket Pharmaceuticals; patent agent at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; inventor at SwimSpray, LLC; and managing member of Chadeayne LLC, a patent prosecution firm. Andrew earned a BA in Chemistry from Princeton, a PhD in Chemistry from Cornell, and a JD from the George Washington University Law School.
Chief Technology Officer & Chief Marketing Officer
Davis Wuolle leads CaaMTech’s technology and marketing functions. His expertise lies in finding technological solutions to a diverse range of problems, from complex scientific research to digital marketing. Davis has over fifteen years of experience working with technology startups in Canada and the United States.
Chief Scientific Officer
Dr. Discordia brings over 30 years of pharmaceutical and biotechnology industry experience to the CaaMTech team highlighted by a 26-year tenure with pharmaceutical giant Bristol Myers Squibb. Dr. Discordia will lead CaaMTech’s pharmaceutical development team by advancing a portfolio of novel compounds from the company’s vast library into clinical trials.
General Counsel & Director of Intellectual Property
Michael (Mike) O’Shaughnessy has served as an attorney and advisor to businesses in the life sciences and pharmaceutical industries for over 20 years. As the company’s Director of Intellectual Property, Mike manages CaaMTech’s vast intellectual property portfolio, protecting CaaMTech’s unmatched library of novel compounds and formulations.